Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PRTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRTCPureTech Health$18.45-0.8%$17.89$13.30▼$25.00$443.27M1.114,610 shs3,751 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRTCPureTech Health+5.27%+3.51%-4.44%+9.78%-19.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPRTCPureTech Health2.4794 of 5 stars3.85.00.00.01.80.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePRTCPureTech Health 3.50Strong Buy$45.00148.69% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPRTCPureTech Health$4.83M89.99$2.40 per share7.53$17.04 per share1.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPRTCPureTech HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPRTCPureTech HealthN/A9.339.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPRTCPureTech Health0.04%Insider OwnershipCompanyInsider OwnershipPRTCPureTech Health5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePRTCPureTech Health10024.02 million22.75 millionNot OptionableOBI, PRTC, OXB, and HZD HeadlinesRecent News About These CompaniesPureTech CEO Bharatt Chowrira steps downJuly 16 at 4:21 PM | thepharmaletter.comTPureTech Health CEO Bharatt Chowrira ResignsJuly 16 at 6:45 AM | marketwatch.comPureTech Announces Leadership TransitionJuly 16 at 3:03 AM | businesswire.comPureTech Health announces board chair Raju Kucherlapati steps downJuly 10, 2025 | investing.comPureTech Health plc (PRTC) Income Statement - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comPureTech Announces Board ChangeJuly 8, 2025 | businesswire.comPureTech Health (NASDAQ:PRTC) Trading 0.6% Higher - Still a Buy?July 1, 2025 | marketbeat.comWhy This Biotech Stock Just Doubled In A Single DayJune 26, 2025 | benzinga.comPureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF TrialMay 22, 2025 | businesswire.comPureTech’s deupirfenidone shows strong and durable efficacyMay 21, 2025 | thepharmaletter.comTPureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)May 9, 2025 | businesswire.comPureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International ConferenceMay 1, 2025 | finance.yahoo.comPureTech to Present Results from Phase 2b ELEVATE…May 1, 2025 | pharmiweb.comPPureTech Health plc (PRTC) Q4 2024 Earnings Call TranscriptApril 30, 2025 | seekingalpha.comPureTech Announces Annual Results for Year Ended December 31, 2024April 30, 2025 | businesswire.comPureTech Health Stock Price, Quotes and Forecasts | NASDAQ:PRTC | BenzingaApril 22, 2025 | benzinga.comLeerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)April 10, 2025 | markets.businessinsider.comPureTech Appoints Peel Hunt as Joint UK Corporate BrokerApril 9, 2025 | businesswire.comPureTech Appoints Peel Hunt as Joint UK Corporate BrokerApril 9, 2025 | businesswire.comPureTech Health Shares Fall After Nordic Capital Withdraws Offer PlanApril 8, 2025 | marketwatch.comNordic Capital steps away from potential PureTech Health buyoutApril 7, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThese 3 Dividend Stocks Combine Strong Yields With UpsideBy Chris Markoch | June 20, 2025View These 3 Dividend Stocks Combine Strong Yields With UpsideJoby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?By Jeffrey Neal Johnson | July 14, 2025View Joby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?Aeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionBy Dan Schmidt | July 2, 2025View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionAST SpaceMobile's Signal Strengthens as Stock Nears OrbitBy Jeffrey Neal Johnson | June 25, 2025View AST SpaceMobile's Signal Strengthens as Stock Nears OrbitRobinhood Director Sells Millions, But HOOD Stock Eyes GainsBy Gabriel Osorio-Mazilli | June 19, 2025View Robinhood Director Sells Millions, But HOOD Stock Eyes GainsOBI, PRTC, OXB, and HZD Company DescriptionsPureTech Health NASDAQ:PRTC$18.37 -0.23 (-1.23%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
